Skip to main content

Table 1 Participant characteristics at baseline

From: The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR

Variable

Drug allocation

Total, N = 40

Placebo, n = 20

Primaquine, n = 20

Age in year, mean (95% CI)

31.7 (24.4–39.0)

23.4 (17.1–29.6)

27.5 (22.6–32.4)

Male (%)

14 (70)

12 (60)

26 (65)

Weight kg, mean (95% CI)

44.5 (39.7–49.3)

44.6 (38.2–50.9)

44.5 (40.6–48.5)

Complete 12-month FU (%)

16 (80)

16 (80)

32 (80)

Hba g/dl, mean (95% CI)

13.7 (13.1–14.4)

13.5 (12.9–14.1)

13.6 (13.2–14.1)

Age in year, median (Range)

32.5 (10–76)

19 (10–54)

25.5 (10–76)

Weight kg, mean (95% CI)

44.5 (39.7–49.3)

44.6 (38.2–50.9)

44.5 (40.6–48.5)

Recruitment year, n

 Jun-16

9

9

18

 Jun-17

11

11

22

uPCR

 During surveys of MDA trial

  Mono-PV infection

16

17

33

  Mixed PV infection

4

3

7

 At day 0

  PV infection

0

0

0

  1. aHaemoglobin